82
Participants
Start Date
December 31, 2012
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
BIIB033 (anti-LINGO-1 mAb)
100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
Placebo
via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
Research Site, Parkville
Research Site, Sydney
Research Site, Bruges
Research Site, Brussels
Research Site, Ghent
Research Site, Limbourg
Research Site, Halifax
Research Site, Ottawa
Research Site, Olomouc
Research Site, Prague
Research Site, Glostrup Municipality
Research Site, Bamberg
Research Site, Berlin
Research Site, Dresden
Research Site, Düsseldorf
Research Site, Tübingen
Research Site, Budapest
Research Site, Fidenza
Research Site, Florence
Research Site, Milan
Research site, Roma
Research Site, Barcelona
Research Site, Córdoba
Research Site, Palmar
Research Site, Seville
Research Site, Valencia
Research Site, Lund
Research Site, Stockholm
Research Site, Birmingham
Research Site, Glasgow
Research Site, Leicester
Research Site, London
Lead Sponsor
Biogen
INDUSTRY